Molecular Research and New Therapy in Melanoma
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 307
Special Issue Editor
Interests: molecular cancer; metastasis; protein kinase C; micro peptide; breast cancer; cancer stem cells; melanoma; tumor biology; targeted therapy
Special Issue Information
Dear Colleagues,
Melanoma is the most aggressive of all skin cancers due to its metastatic nature. Potential advancements in melanoma therapy rely on advanced research that addresses the molecular complexity of this cancer. The current scenario requires both advanced scientific knowledge coupled with empirical evidence in identifying new therapeutic targets in order to improve drug sensitivity and overcome secondary resistance. Innovative research approaches focusing on the molecular mechanisms of the tumor microenvironment provides key insights into either reducing or eliminating melanoma. The aim of this Special Issue is to present a unified collection of the latest research articles and findings on melanoma, focusing on identifying new realms of molecular mechanisms and biomarkers and hopefully prompting the invention of significant molecular targeted therapies. This Special Issue includes the latest research articles on the mutations, signaling pathways, and immune responses that determine melanoma progression. This unified collection aims to describe how the latest findings are proving beneficial in developing innovative therapies, including targeted treatments and immunotherapies for melanoma patients. These research findings can pave the way for transforming preclinical trials into clinical practices. We welcome original research articles and reviews that address the molecular mechanisms behind melanoma and novel therapies related to the disease.
Dr. Vijayasteltar B Liju
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- melanoma
- metastasis
- targeted therapies
- immunotherapy
- tumor microenvironment
- combination therapies
- molecular pathways
